慢性乙型肝炎的治疗—2009年及未来

Treatment of Chronic Hepatitis B Infection - Year 2009 and Beyond
George KK Lau
Department of Medicine, The University of Hong Kong
On the second day of APASL, Professor George KK Lau gave a lecture on the treatment of chronic hepatitis B infection in 2009 and beyond. He said “We will need better therapy which will induce lasting off-treatment sustained disease remission.

This will mean sustained full hepatitis B e-antigen seroconversion or even hepatitis B surface antigen seroconversion. Being able to do this will shorten the duration of therapy and hence to avoid the cost, side effect and the risk of development of viral resistance with the use of prolonged nucleos(t)ide therapy.”

Otherwise, he pointed out that in order to facilitate better monitoring of anti-hepatitis B therapy, the development of standardized assay for serum viral antigen quantitation would be of great value.

In the end, he believed that in the very near future, based on advanced technology platform available for more detailed genetic, immunological and virological studies, we would be able to further optimize hepatitis B therapy in a personalized fashion, and a more rational basis for combination therapy would be developed.

在APASL会议的第二天，George KK Lau教授做了题为“Treatment of Chronic Hepatitis B Infection - Year 2009 and Beyond”的大会报告。他指出我们需要更好的治疗方法以达到治疗结束后持久的病情缓解。这意味着需要达到乙肝e抗原血清学转换，甚至表面抗原血清学转换。从而可以缩短疗程，避免因长期应用核苷（酸）类药物而造成的费用、副作用及病毒耐药风险的增加。同时，为了更好的监测乙肝抗病毒治疗，血清病毒抗原定量的标准化检测方法的发展将有巨大价值。George KK Lau教授相信，在不久的将来，随着遗传学、免疫学及病毒学相关研究的发展，我们将能以个体化的形式进一步优化乙肝抗病毒治疗，并且联合治疗将得到更大发展。